Ropivacaine Hydrochloride has 36 known drug interactions based on U.S. FDA drug labeling data. 31 are classified as major interactions requiring close medical supervision. Notable interactions include combinations with Acetaminophen, Acetazolamide, Articaine. Patients taking Ropivacaine Hydrochloride should inform their healthcare provider of all current medications — including over-the-counter drugs and supplements — to avoid potentially harmful combinations. Data sourced from OpenFDA and the NIH National Library of Medicine.
- Total
- 36
- Major
- 31
- Moderate
- 5
Major (31)
- Ropivacaine Hydrochloride + Acetaminophen— Increased risk of developing methemoglobinemia when concurrently exposed to acetaminophen.
- Ropivacaine Hydrochloride + Acetazolamide— Increased risk of developing methemoglobinemia when concurrently exposed to sulfonamides.
- Ropivacaine Hydrochloride + Articaine— Toxic effects are additive; use with caution in patients receiving other local anesthetics.
- Ropivacaine Hydrochloride + Benzocaine— Increased risk of methemoglobinemia when concurrently exposed to ropivacaine.
- Ropivacaine Hydrochloride + Bupivacaine— Toxic effects are additive; use with caution in patients receiving other local anesthetics.
- Ropivacaine Hydrochloride + Chloroquine— Increased risk of developing methemoglobinemia when concurrently exposed to chloroquine.
- Ropivacaine Hydrochloride + Cyclophosphamide— Increased risk of developing methemoglobinemia when concurrently exposed to cyclophosphamide.
- Ropivacaine Hydrochloride + Dapsone— Increased risk of developing methemoglobinemia when concurrently exposed to dapsone.
- Ropivacaine Hydrochloride + Flutamide— Increased risk of developing methemoglobinemia when concurrently exposed to flutamide.
- Ropivacaine Hydrochloride + Fluvoxamine— Strong CYP1A2 inhibitor reduced plasma clearance of ropivacaine by 70%, leading to increased ropivacaine plasma levels.
- Ropivacaine Hydrochloride + Hydroxyurea— Increased risk of developing methemoglobinemia when concurrently exposed to hydroxyurea.
- Ropivacaine Hydrochloride + Ifosfamide— Increased risk of developing methemoglobinemia when concurrently exposed to ifosfamide.
- Ropivacaine Hydrochloride + Lidocaine— Toxic effects are additive; use with caution in patients receiving other local anesthetics.
- Ropivacaine Hydrochloride + Mepivacaine— Toxic effects are additive; use with caution in patients receiving other local anesthetics.
- Ropivacaine Hydrochloride + Metoclopramide— Increased risk of developing methemoglobinemia when concurrently exposed to metoclopramide.
- Ropivacaine Hydrochloride + Nitric Oxide— Increased risk of developing methemoglobinemia when concurrently exposed to nitric oxide.
- Ropivacaine Hydrochloride + Nitrofurantoin— Increased risk of developing methemoglobinemia when concurrently exposed to nitrofurantoin.
- Ropivacaine Hydrochloride + Nitroglycerin— Increased risk of developing methemoglobinemia when concurrently exposed to nitroglycerin.
- Ropivacaine Hydrochloride + Nitroprusside— Increased risk of developing methemoglobinemia when concurrently exposed to nitroprusside.
- Ropivacaine Hydrochloride + Nitrous Oxide— Increased risk of developing methemoglobinemia when concurrently exposed to nitrous oxide.
- Ropivacaine Hydrochloride + Para-Aminosalicylic Acid— Increased risk of developing methemoglobinemia when concurrently exposed to para-aminosalicylic acid.
- Ropivacaine Hydrochloride + Phenobarbital— Increased risk of developing methemoglobinemia when concurrently exposed to Phenobarbital.
- Ropivacaine Hydrochloride + Phenytoin— Increased risk of developing methemoglobinemia when concurrently exposed to phenytoin.
- Ropivacaine Hydrochloride + Prilocaine— Increased risk of methemoglobinemia when concurrently exposed to ropivacaine.
- Ropivacaine Hydrochloride + Primaquine— Increased risk of developing methemoglobinemia when concurrently exposed to primaquine.
- Ropivacaine Hydrochloride + Procaine— Toxic effects are additive; use with caution in patients receiving other local anesthetics.
- Ropivacaine Hydrochloride + Quinine— Increased risk of developing methemoglobinemia when concurrently exposed to quinine.
- Ropivacaine Hydrochloride + Rasburicase— Increased risk of developing methemoglobinemia when concurrently exposed to rasburicase.
- Ropivacaine Hydrochloride + Sulfasalazine— Increased risk of developing methemoglobinemia when concurrently exposed to sulfasalazine.
- Ropivacaine Hydrochloride + Tetracaine— Increased risk of methemoglobinemia when concurrently exposed to tetracaine.
- Ropivacaine Hydrochloride + Valproate Sodium— Increased risk of developing methemoglobinemia when concurrently exposed to sodium valproate.
Moderate (5)
- Ropivacaine Hydrochloride + Amide— 7 DRUG INTERACTIONS Patients who are administered local anesthetics are at increased risk of developing methemoglobinemi…
- Ropivacaine Hydrochloride + Amiodarone— Class III antiarrhythmic drug; specific interaction studies not performed but caution is advised.
- Ropivacaine Hydrochloride + Imipramine— Possible interaction via competitive inhibition of CYP1A2 metabolism; caution advised.
- Ropivacaine Hydrochloride + Ketoconazole— CYP3A4 inhibitor caused 15% reduction in plasma clearance of ropivacaine.
- Ropivacaine Hydrochloride + Theophylline— Possible interaction via competitive inhibition of CYP1A2 metabolism; caution advised.